| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $3.1M | — | -1.9% |
| SG&A Expense | $2.3M | — | -68.4% |
| Operating Income | -$5.4M | — | +47.8% |
| Net Income | -$5.4M | — | +47.5% |
| EPS (Basic) | -$1.61 | — | -2200.0% |
| EPS (Diluted) | -$1.61 | — | -2200.0% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Current Assets | $2.1M | +39.0% | -30.4% |
| Total Assets | $4.9M | +12.3% | +20.8% |
| Current Liabilities | $7.3M | +2.8% | -16.6% |
| Total Liabilities | $14.8M | +17.0% | +25.2% |
| Stockholders' Equity | -$9.8M | -19.5% | -27.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$2.7M | — | +17.4% |
| Financing Cash Flow | $2.9M | — | -28.2% |